Oramed, Genomma Lab in JV for oral COVID-19 vaccine in Mexico; BD in Latin America

Oravax Medical, a unit of Oramed Pharmaceuticals (NASDAQ, TASE:ORMP), and Genomma Lab Internacional (BMV:LABB) formed of a 50/50 joint venture to develop and commercialize Oravax’s oral COVID-19 vaccine candidate in Mexico.

Genomma Lab is expected to contribute resources to the joint venture’s oral COVID-19 vaccine development, as well as clinical, regulatory, and commercial activities in Mexico. Genomma Lab also will support the business development process and vaccine roll-out throughout Latin America. 

Under the accord, Oramed and Genomma Lab plan to enter a $20-million share swap based on the average closing price of their respective shares during the past 15 trading days. Genomma Lab has also committed to participate in a future investment in Oravax.

“The synergies between our respective companies’ core competencies made it clear that the combination of our particular strengths represents a unique and significant opportunity,” Nadav Kidron, CEO of Oramed, said in a statement.

Rodrigo Herrera, chairman of Genomma, said that based on initial discussions with regulatory authorities, the companies are already beginning to prepare for a Phase 2 trial immediately after successful completion of the Phase 1 trial of the oral vaccine in South Africa.

“Oravax’s oral vaccine’s superior target profile makes it an ideal candidate for an expedited approval process,” Mr. Herrera said.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.